Viewing Study NCT02681094


Ignite Creation Date: 2025-12-25 @ 1:45 AM
Ignite Modification Date: 2026-03-12 @ 1:32 PM
Study NCT ID: NCT02681094
Status: COMPLETED
Last Update Posted: 2018-10-10
First Post: 2016-02-10
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Type 2 Diabetes Mellitus View
None Inadequate Glycaemic Control View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Diabetes Mellitus Type 2, View
None saxagliptin, View
None dapagliflozin, View
None metformin View